burger

A pharmaceutical company
specialising in biological
medicinal products

15 medicines

prescribed to

hospital

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care
4

BIOPRODUCTION SITES in the world

2/3

of LFB’s biomedicinal products are intended for the treatment of patients with rare diseases

Group executive committee

Committee’s composition
€ 350 M in turnover

in 2019

>20

medical specialties that regularly use
LFB’s medicines

All news

2:34

The LFB 2021 coporate Brochure in video

2:33

LFB Arras plant under construction in October 2020 in video

2:43

LFB’s commitment to patients, with AFNP

2:54

LFB's commitment to patients and to IRIS association.

All videos
Découvrez la nouvelle Brochure du LFB

Take a look at the new LFB corporate brochure!

LFB opens the doors of the future Arras Factory

LFB is committed to patients suffering from rare coagulation disorders at GTH Congress 2021.

LFB is committed to Von Willebrand disease at EAHAD 2021

LFB’s commitment to patients, with AFNP

CAHPP green index: LFB obtains A++ label

LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA'S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19

LFB announces FDA approval of SEVENFACT®, a recombinant coagulation Factor VIIa

2:34

The LFB 2021 coporate Brochure in video

there is 1 month

2:33

LFB Arras plant under construction in October 2020 in video

there is 3 months

2:43

LFB’s commitment to patients, with AFNP

there is 3 months

2:54

LFB's commitment to patients and to IRIS association.

there is 1 year